London stock market listing of up to £45bn looms as GSK investors vote for demerger

UK pharmaceutical to spin off brands such as Sensodyne, Voltaren and Panadol into Haleon in largest listing since 2011

Investors in the British pharmaceuticals giant GSK have voted to approve a demerger of its consumer brands into a new company, Haleon, firing the starting gun on the largest London stock market listing in a decade.

Shares in Haleon are scheduled to start trading on Monday 18 July, after investors in GSK - previously GlaxoSmithKline - voted to approve the demerger. The FTSE 100 company won 99.8% of the votes cast at a general meeting on Wednesday at a hotel by London's Heathrow airport.